Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

RHEI Begins Final China Trial for Oral Cadidiasis Product

publication date: Dec 8, 2008

RHEI Pharmaceuticals has begun the final China clinical trial for Tibozole, a locally active antifungal with low dose miconazole in a patented mucoadhesive system. Tibozole will attempt to approve its efficacy as a treatment for oral candidiasis, a condition that affects immuno-compromised patients with HIV/AIDS and cancer patients undergoing chemotherapy. RHEI, a venture-backed company, has offices in the US and Belgium, but its operations are in China. More details.

Stock Symbols: (NYSE: JNJ) (NSDQ: APPA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here